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ABSTRACT
VNP20009 is a very effective anti-cancer agent and can specifically target 
tumors and inhibit tumor growth. It was assumed that the tumor targeting ability 
of VNP20009 correlated to its anticancer capacity. However, our observation 
contradicted to this assumption. Three VNP20009 mutant strains (∆slyA, ∆STM3120 
and ∆htrA) with reduced fitness in normal tissues and unchanged fitness in tumors 
partially or completely lost their anti-cancer capacities. The genes slyA, STM3120 
and htrA were required for survival within macrophages and were indispensable for 
tumor microenvironment remodeling by VNP20009. The infiltration of immune cells 
occurred less in the tumors of mice infected with the mutant strains. In addition, the 
mRNA levels of TNF-α and IL-1β were significantly decreased in the tumors of mice 
treated with the mutant strains. Our results indicate that the immune responses 
elicited by bacteria rather than the bacterial titer in tumors play a “decisive” role in 
VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for 
the underlying mechanism of bacterial cancer therapy.
INTRODUCTION
One of the major problems in the current cancer 
therapies is poor tumor targeting specificity. To address 
this limitation, bacterial cancer therapy was developed. 
Salmonella enterica serovar Typhimurium was reported 
to preferentially accumulate in tumors and inhibit tumor 
growth [1]. However, wild-type S. enterica is highly 
pathogenic for humans. As such, avirulent S. enterica 
A1-R and VNP20009 were developed for therapeutic 
applications. A1-R is auxotrophic for leucine and arginine. 
And it has been proven to eradicate primary and metastatic 
tumors in nude mouse models of prostate, breast, ovarian 
and pancreatic cancer, etc. [2–7]. VNP20009, with double 
mutations in msbB and purI, is another attenuated S. 
enterica and has been proven safe in phase I clinical trials. 
Furthermore, VNP20009 was most wildly used to deliver 
anticancer agents and carry shRNA-expressing plasmids 
[8–12]. However, VNP20009 failed to target tumors and 
inhibit tumor growth in the phase I study. Therefore, 
additional studies are required to study the factors 
affecting tumor colonization and anti-tumor effects. To 
investigate this, a high-throughput method was used to 
screen for S. enterica promoters and genes that expressed 
in tumors [13, 14]. Furthermore, in vivo gene mutation 
assay showed that SPI-2, invA and flagella (fla) are 
essential for the anticancer ability of S. enterica [15, 16].
Macrophages play a pivotal role in bacterial 
clearance during an infection. After being phagocytosed 
by macrophages, S. enterica modify the vacuoles where 
they reside and subsequently disseminate throughout 
the body [17]. Fileds and his colleagues showed that 
the mutants that cannot survive within macrophages are 
avirulent [18]. As such, the capacity of S. enterica to cause 
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systematic infection relies on its ability to survive and 
replicate within macrophages. However, the anticancer 
ability of the mutants lacking macrophage survival ability 
has not been well studied.
In this study, we knocked out three genes related to 
VNP20009 survival within macrophages. The gene slyA 
and STM3120 are transcriptional regulators and HtrA is 
a stress protein for degrading the damaged and misfolded 
proteins. These genes perform different functions for 
bacterial survival within macrophages. Although ∆slyA, 
∆STM3120 and ∆htrA displayed reduced fitness in 
spleen and unchanged fitness in tumors, their anticancer 
capacities were partially or completely abrogated. 
Therefore, we further examined the immune responses 
by comparing immune cells and cytokines in tumor 
infected by VNP20009 with the mutants, attempting to 
elucidate the mechanism of the mutants with reduced 
anti-cancer capacity.
RESULTS
In vitro characterization of ∆slyA, ∆STM3120 
and ∆htrA 
Because the genes slyA, STM3120 and htrA were 
reported to play vital roles in macrophage survival, each 
of the mutants was characterized using a gentamicin 
protection assay. As shown in Figure 1C, the uptake of 
bacteria was not impaired in the mutant groups compared 
with that in the VNP20009 group. However, in contrast 
to VNP20009, the replication rates of all mutants were 
decreased over five hours. VNP20009 displayed a 2.5- to 
10- fold increase in replication rate in macrophages at 
five hour post infection compared with the mutant 
groups (Figure 1D).
These mutants were then characterized by probing 
their growth curve in vitro, and the growth of mutants in 
LB showed no defects (Figure 1A). In addition, both the 
mutants and VNP20009 were able to infect B16F10 cells, 
and there were no significant differences between the 
mutants and VNP20009 with respect to replication rates 
(Figure 1B). Collectively, these results suggested that 
the genes slyA, STM3120 and htrA were not required for 
VNP20009 replication in melanoma cells, but were vital 
for VNP20009 to survive within macrophages.
The biodistribution of the mutants in tumor 
bearing mice
To determine the biodistribution of the mutants, 
1 × 105 colony forming unit (CFU) S. enterica were 
inoculated into tumor-bearing mice when the tumor size 
reached 150 mm3. VNP20009 and all of the mutants 
targeted the tumor at similar levels, reaching above 
109 CFU/g in tumor 3 days post infection (P > 0.05) 
(Figure 2A). However, the bacterial loads of the mutants 
were significantly lower than that of VNP20009 in spleen, 
which is the main target of bacteria (P < 0.05) (Figure 2B). 
Additional calculations were performed to determine the 
ratio between the bacterial loads in tumor and spleen. 
The ratios of the ∆slyA, ∆STM3120 and ∆htrA mutants 
were ten times higher than that of VNP20009 (Figure 2C). 
Overall, ∆slyA, ∆STM3120 and ∆htrA displayed greater 
therapeutic potentials, as the mutants showed reduced 
bacterial accumulation in normal tissues and unchanged 
tumor fitness.
The anticancer capacities of the mutants
Because the mutants displayed a higher tumor to 
spleen ratio than VNP20009, their anticancer activities 
were further investigated. The tumor suppression 
capacities of the mutants were partially or completely 
eliminated (P < 0.05) (Figure 3). On the 9th day of 
infection, the tumor volumes of mice treated with 
VNP20009 were significantly lower than those in the 
PBS group (Figure 3A). Tumor doubling time and 
tumor growth delay were significantly increased in the 
mice treated with VNP20009 than those in the PBS 
group (P < 0.05) (Figure 3B and 3C). However, the mice 
infected with ∆slyA and ∆STM3120 showed only a partial 
tumor growth delay compared with those infected with 
VNP20009 (P < 0.05). More importantly, ∆htrA failed 
to suppress tumor growth. The tumor doubling time was 
remarkably decreased from 2.69 days (CI, 2.78 d to 2.51 d) 
in the VNP20009 group to 2.4 days (CI, 2.52 d to 2.28 d) 
in the ∆htrA group (Figure 3C). The tumor growth delay 
was significantly decreased from 23.67 days (CI, 22.99 
d to 24.47 d) in the VNP20009 group to 17.69 days (CI, 
17.59 d to 17.70 d) in the ∆htrA group (Figure 3B). 
In order to definitively link the genes slyA, 
STM3120 and htrA to the diminished antitumor activities, 
the anticancer activities of ∆slyA, ∆STM3120 and ∆htrA 
mutants were studied after complementation. Intact 
copies of the genes were cloned into pHQ-003-F, and 
the complementing plasmids were transformed into the 
corresponding mutants, respectively. After confirming 
the proteins were precisely expressed, we next assessed 
their antitumor properties (Figure 3D). As shown in 
Figure 3E, 3F and 3G, the anticancer capacities of the 
mutants were partially or completely reversed when 
the mutants were complemented with a copy of the 
corresponding gene. The presence of the vector alone did 
not improve the anticancer ability. These results indicated 
that the genes slyA, STM3120 and htrA are vital for the 
anticancer ability of VNP20009.
The analysis of the tumor immune-environment 
in mice 
The anti-cancer ability of S. enterica relies 
on its ability to recruit immune cells into the tumor 
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microenvironment [19]. Therefore, whether the 
mutants can promote proper immune responses 
in tumor microenvironment remains unclear. We 
analyzed CD4+ T cells, macrophages and granulocytes 
in tumor, which are reported to be responsible for the 
anticancer ability of S. enterica [19–21]. The results 
indicated that in contrast to the mutants, VNP20009 
facilitated the migration of CD4+ T cells, macrophages 
and granulocytes into the tumor (Figure 4A, 4B, 4C). 
The ∆htrA mutant, which completely lost its tumor 
suppressive capacity, induced 1.2% of CD4+ T cells on 
the 3rd day post infection. This level was only one fifth 
of that induced by VNP20009 (P < 0.05) (Figure 4A). 
The macrophages and granulocytes in the tumor of ∆htrA 
group were decreased by more than 40% compared with 
that of VNP20009 group (P < 0.05) (Figure 4B, 4C). 
In addition, the ∆slyA and ∆STM3120 treatments led a 
significant reduction of immune cells compared with the 
VNP20009 treatment (P < 0.05) (Figure 4A, 4B, 4C). 
Generally, the ability of the mutants to recruit immune 
cells into the tumor was reduced.
Previous studies showed that TNF-α and IL-1β are 
essential for bacterial cancer therapy. Thus, we further 
analyzed the expression of TNF-α and IL-1β in the 
tumors of bacteria-treated mice. The results showed 
that the mRNA levels of TNF-α and IL-1β in the mutant 
groups were significantly down-regulated compared with 
those in the VNP20009 group (P < 0.05) (Figure 4D, 
4E). The expression of TNF-α in the VNP20009 group 
was increased 238-fold compared with that in the 
PBS control. However, the mice treated with ∆slyA, 
∆STM3120 and ∆htrA mutants exhibited only 93-, 128- 
and 28- fold increase in TNF-α expression, respectively, 
compared with the mice treated with PBS (Figure 4D). 
Although IL-1β was significantly increased after bacterial 
therapy, the expression of IL-1β in the VNP20009 group 
Figure 1: Characterization of VNP20009 and its mutants. (A) Growth rates of VNP20009 and its mutants in vitro. Date are shown 
in mean ± SEM. (B) Replication rates of VNP20009 and its mutants in B16F10 cells. Date are shown in mean ± SEM. (C) The number of 
intracellular bacteria in RAW 264.7 cell after invasion by VNP20009 and its mutants. Date are shown in mean ± SEM. (D) Replication rates 
of VNP20009 and its mutants within RAW 264.7 cell. Date are shown in mean ± SEM, **P < 0.01.
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was increased greater than 18- fold compared with the 
mutant groups (P < 0.05) (Figure 4E). These results 
indicated that the reduced anticancer activities of the 
mutants, which were deleted the genes slyA, STM3120 
and htrA in the VNP20009 background, might be 
ascribed to the inability to activate immune-mediated 
antitumor responses.
DISCUSSION
VNP20009 is a live anti-cancer agent and has 
some unique properties to make it better than traditional 
methods, including chemotherapy and radiation. For 
example, VNP20009 can specifically target tumors, sense 
the local environment and respond to external signals and 
can be engineered at genetic levels [1]. However, it failed 
in phase I clinical trials because of no antitumor effects 
[22]. Thus, tremendous efforts, including whole genome 
sequencing, were performed to improve the safety profile 
and tumor targeting ability [23]. However, the underlying 
mechanism of the anticancer capacity of VNP20009 
still remains unclear. In this study, we knocked out the 
genes slyA, STM3120 and htrA, which are responsible for 
bacterial survival within macrophages, in the background 
of VNP20009 to study the relationship between bacterial 
intramacrophage survival ability and antitumor capacity. 
We found that all the mutants partially or completely lost 
their antitumor capacities, although they preferentially 
targeted and colonized tumor. The result indicates that in 
contrast to the former assumption, the bacterial burden in 
tumor does not play a decisive role in bacterial anticancer 
ability, which is consistent with previous observations 
[24, 25].
To establish a systematic infection, S. enterica 
must survive and replicate within the host macrophages 
where it is exposed to poor nutrients and microbicidal 
environments [26]. Production of reactive oxygen 
species (ROS) and nitric oxide is an important feature 
of intracellular bactericidal activities, which can be 
prevented by expressing slyA, STM3120 and htrA genes. 
HtrA possesses protease and chaperone activities, 
which are temperature dependent in vitro [27, 28]. 
The chaperone activity of HtrA predominates at low 
temperatures, whereas protease activity is present at 
high temperatures. In the present study, the growth rate 
of ∆htrA in vitro was not impaired at 37°C, although 
the growth of ∆htrA was reported to be inhibited 
at 46°C or higher [27]. In addition, Mutunga et al. 
found that ∆htrA was attenuated because of increased 
sensitivity to oxidative stress [29]. Thus, ∆htrA mutant 
was evaluated as a live vaccine and used for delivering 
recombinant antigens, such as CVD 908-htrA [30]. 
Figure 2: Biodistribution of VNP20009 and its mutants in tumor-bearing mice. VNP20009 and its mutants were 
intraperitoneally inoculated into the tumor-bearing mice. The bacterial titer in spleen and tumor were determined on the third day post 
infection. (A) Bacterial burden of ∆slyA, ∆STM3120 and ∆htrA mutants in tumor compared with VNP20009. Date are shown in mean ± SEM. 
(B) Bacterial burden of ∆slyA, ∆STM3120 and ∆htrA mutants in spleen compared with VNP20009. Date are shown in mean ± SEM, 
**P < 0.01. (C) Tumor/spleen ratio of VNP20009 and the mutants in the tumor bearing mice. Date are shown in mean ± SEM, *P < 0.05, 
**P < 0.01.
Oncotarget81191www.impactjournals.com/oncotarget
Figure 3: Antitumor effects of VNP20009 and its mutants. S. enterica (1 × 105 CFU/mouse) were injected intraperitoneally 
into the tumor-bearing mice when the tumor size reached 150 mm3. Tumor volumes of different groups were compared. (A) Tumor 
volumes of the mice treated with ∆slyA, ∆STM3120 and ∆htrA compared with that treated with VNP20009. Date are shown in mean 
± SEM, *P < 0.05, **P < 0.01. (B) Tumor growth delay of the mice treated with ∆slyA, ∆STM3120 and ∆htrA versus VNP20009. Date are 
shown in mean ± SEM, *P < 0.05, **P < 0.01. (C) Tumor doubling time of the mice treated with ∆slyA, ∆STM3120 and ∆htrA compared 
with that with VNP20009. Date are shown in mean ± SEM, *P < 0.05, **P < 0.01. (D) FLAG expressions from the mutants carrying 
pHQ003-F-slyA, pHQ003-F-STM3120 and pHQ003-F-htrA was detected by western blotting. (E) Tumor volumes of the mice treated 
with ∆slyA-pHQ(slyA) compared with that treated with ∆slyA-pHQ. Date are shown in mean ± SEM, **P < 0.01. (F) Tumor volumes of 
the mice treated with ∆STM3120-pHQ(STM3120) compared with that treated with ∆STM3120-pHQ. Date are shown in mean ± SEM, 
**P < 0.01. (G) Tumor volumes of the mice treated with ∆htrA-pHQ(htrA) compared with that treated with ∆htrA-pHQ. Date are shown 
in mean ± SEM, **P < 0.01.
SlyA, a member of the MarR family of transcription 
factors, is a transcription factor that regulates a large 
number of genes, including S. enterica pathogenicity 
island (SPI)-2 [31, 32]. Because the genes within SPI-2 
were reported to be involved in S. enterica virulence by 
preventing killing by mechanisms involving oxidative 
mechanism and because SPI-2 is required for S. enterica 
survival within macrophages, ∆slyA is sensitive to 
oxidative products of the respiratory burst [33, 34]. 
STM3120 is a predicted citE (citrate lyase) homolog and 
is important during systemic infection in BALB/c mice. 
Santiviago et al. suggested that STM3120 could decrease 
the level of nitric oxide in macrophages [35]. Consistent 
with these findings, our results revealed that the deletion 
of the genes slyA, STM3120 and htrA in the background 
of VNP20009 made the mutants more vulnerable in 
macrophages, although their growth rates in vitro and 
replications in B16F10 cells were not impaired.
The results showed that ∆slyA, ∆STM3120 and ∆htrA 
exhibited the highest tumor to spleen ratio, indicating that 
the tumor specificity of S. enterica was closely related to 
survival capacity within macrophages. When S. enterica 
enters the blood, the immune system is activated to deplete 
bacteria from the circulation system and macrophage is 
probably the most important. Given that S. enterica is 
rapidly subjected to phagocytosis by macrophages, only 
those bacteria capable of replicating within macrophages 
can cause a systematic infection. Thus, S. enterica that is 
incapable of replicating intracellularly is highly attenuated. 
In the present study, ∆slyA, ∆STM3120 and ∆htrA were 
efficiently cleared by macrophages, which could explain 
the low bacterial burden in spleen. 
By contrast, S. enterica in tumors are protected from 
the immune system, and all the mutants accumulated in 
the tumor to the same extent as VNP20009. Although 
the process of bacterial tumor targeting is not entirely 
clear, macrophage was reported not to be a transporter 
of bacteria to tumor, and depleting macrophages did 
not affect tumor colonization [36]. Our results further 
confirmed this finding because the mutants with 
reduced survival within macrophages reached the 
same accumulation level in tumors as VNP20009. In 
addition, S. enterica was found both intracellular and 
extracellular in the tumor, where immune surveillance 
Oncotarget81192www.impactjournals.com/oncotarget
Figure 4: Subpopulation of immune cells and expression of TNF-α and IL-1β in the tumor. VNP20009 and its mutants 
(1 × 105 CFU/mouse) were injected intraperitoneally into the tumor-bearing mice. The immune cells in the tumor were determined on the 
third day post infection. (A) CD4+ T cells in the tumors of mice treated with ∆slyA, ∆STM3120, ∆htrA and VNP20009. Date are shown in 
mean ± SEM, *P < 0.05 for VNP20009 versus individual mutant. (B) Macrophages in the tumors of mice treated with ∆slyA, ∆STM3120, 
∆htrA and VNP20009. Date are shown in mean ± SEM, *P < 0.05 for VNP20009 versus individual mutant. (C) Granulocytes in the tumors 
of mice treated with ∆slyA, ∆STM3120, ∆htrA and VNP20009. Date are shown in mean ± SEM, *P < 0.05 for VNP20009 versus individual 
mutant. (D) TNF-α mRNA expression levels in the tumors colonized by ∆slyA, ∆STM3120, ∆htrA and VNP20009. Date are shown in mean 
± SEM, *P < 0.05, **P < 0.01 for VNP20009 versus individual mutant. (E) IL-1β mRNA expression levels in the tumors colonized by 
∆slyA, ∆STM3120, ∆htrA and VNP20009. Date are shown in mean ± SEM, *P < 0.05 for VNP20009 versus individual mutant.
fails to function [36]. Three days post infection, when the 
bacterial titer reached the highest level in the tumor, all the 
mutants reached the same accumulation level in tumor as 
VNP20009 because the growth and replication rates of the 
mutants within melanoma cells were not impaired [37]. 
These results further reinforce that the low accumulation 
of mutant strains in spleen is due to impaired survival 
ability in macrophages. Although further investigations 
are necessary, the results showed that the bacterial tumor 
selectivity depends on macrophage-mediated clearance 
from the systemic organs and persistence of bacteria in 
the tumor microenvironment, which also partially explain 
Hoffman’s discovery, which showed mutants in STM3120 
and htrA displayed reduced fitness in normal tissue and 
unchanged fitness in tumor [13]. 
Given that ∆slyA, ∆STM3120 and ∆htrA exhibited 
therapeutic potentials with reduced colonization in normal 
organs and unchanged colonization in tumors, they were 
thus validated for their anticancer activities. All of the 
mutants partially or completely lost their anticancer 
abilities. When the mutants were complemented with 
respective genes, their antitumor activities were partially 
or completely restored. In addition, the immune cells 
in the tumors of mice infected with the mutants were 
significantly decreased. Previous studies showed that the 
anti-tumor effects of S. enterica depend on the functional 
role of the MyD88-TLR pathway, and S. enterica enhances 
anti-tumor immunity by inhibiting tumor indoleamine 2, 
3-dioxygenase 1 expression and inducing gap junctions 
in tumors [20, 38, 39]. Our results indicated the genes 
slyA, STM3120 and htrA, which are indispensable for 
the anticancer activity of VNP20009, are required for 
VNP20009 to induce the immune cells and exert an anti-
tumor effect. 
Furthermore, TNF-α and IL-1β are important for 
the tumor suppressive effects of S. enterica. Kim et al. 
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found that the co-administration of recombinant TNF-α 
could prolong the tumor-suppressive effects of ΔppGpp 
Salmonella [25]. In our study, TNF-α was significantly 
decreased in the mice treated with the mutants. In addition, 
the mutants with impaired anticancer ability induced far 
less IL-1β than VNP20009. A recent study showed that the 
impaired anticancer ability of MG1655 (LPS-competent 
E.coli), which displayed similar tumor targeting capacity 
as S. enterica, is due to reduced IL-1β expression [25]. 
The result may also explain why the S. enterica mutants 
with unchanged tumor targeting ability failed to suppress 
tumor growth.
In conclusion, we created ∆slyA, ∆STM3120 and 
∆htrA mutants that had similar tumor targeting abilities, 
but reduced anticancer capacities compared to VNP20009. 
We found that the survival ability within macrophages can 
increase the bacterial burden in normal organs without 
affecting the bacterial tumor targeting ability. In addition 
to this finding, immune cells and cytokines within tumors, 
rather than the bacterial burden in tumors, are responsible 
for the anticancer activity of VNP20009. The current study 
is the first to show the relationship between macrophage 
intracellular survival and anticancer activity and thus 
provides novel insights into bacterial cancer therapy.
MATERIALS AND METHODS
Bacterial strains, cell lines, and mice
VNP20009 is a purine auxotrophy, which deletes 
msbB from S. enterica ATCC 14028S [8]. All the mutants, 
namely ∆slyA, ∆STM3120 and ∆htrA with a deletion of 
slyA, STM3120 or htrA in VNP20009 were gifts from 
Prof. Shi’s lab. All the strains of S. enterica were cultured 
in Luria Broth (LB) or on agar plates using standard 
procedures. B16F10 melanoma cells were obtained from 
American Type Culture Collection (ATCC, USA) and 
were cultured in 5% CO
2
 in a humidified atmosphere in 
Dulbecco’s modified Eagle’s media (DMEM) supplemented 
with 10% fetal bovine serum (FBS). Six-week-old female 
C57BL/6 mice were purchased from the Comparative 
Medicine Center of Yangzhou University and maintained 
in pathogen-free conditions for one week before treatments.
Quantification of S. enterica in tumor 
Briefly, 1 × 105 B16F10 cells were subcutaneously 
inoculated into the mid-right flank of C57BL/6 mice. When 
the tumor size reached 150 mm3, mice were randomly 
divided into VNP20009 group, ∆slyA group, ∆STM3120 
group and ∆htrA group, with each group containing of at 
least 4 mice. S. enterica was grown overnight in LB and 
was diluted at a ratio of 1:100 into fresh LB. When optical 
density (OD) at 600nm was between 0.7 and 1.0, S. enterica 
with 1 × 108 CFU were obtained through centrifuging 
and suspended in phosphate buffered saline (PBS). 
S. enterica with 1 × 105 CFU were obtained by a serial 
dilution and intraperitoneally injected into tumor-bearing 
mice. The mice were sacrificed 3 days after S. enterica 
injection. Spleen and tumor were homogenized in 2 ml 
of PBS to release S. enterica and then plated on LB agar 
by a serial dilution. After 16 h of culture at 37°C, the titer 
of S. enterica was determined by counting colonies and 
dividing them by the weight of the tissue (CFU/g) [40]. 
Anti-tumor assay in vivo
1 × 105 B16F10 cells were subcutaneously 
inoculated into the mid-right flank of C57BL/6 mice. 
When the tumor size reached 150 mm3, tumor bearing 
mice were randomly divided into groups, with each 
group containing 8 mice. For comparing the antitumor 
activities of the mutants and VNP20009, 1 × 105 CFU S. 
enterica were intraperitoneally inoculated into the tumor-
bearing mice. For complementation assay, the mutants 
carrying corresponding plasmids and the mutants were 
intraperitoneally inoculated into the tumor-bearing mice, 
respectively. The length and width of the tumors were 
measured every two days by using a Vernier caliper 
(Mytutoyo Co., Japan) across two perpendicular diameters. 
Tumor volume was calculated using the following formula: 
tumor volume = length × width2 × 0.52. 
Flow cytometry 
As mentioned above, tumor bearing mice were 
randomly divided into 5 groups, with each group 
containing 4 mice. When the tumor size reached 150 mm3, 
1 × 105 S. enterica were intraperitoneally inoculated 
into the tumor-bearing mice. The tumor-bearing mice 
were sacrificed on the third day. According to Bayne 
and Vonderheide’s work, tumors were collected post 
infection for subpopulation analysis of immune cells [41]. 
The tumor was digested by collagenase IV. A single 
cell suspension, which was obtained using a 40-μm cell 
falcon, was incubated in red blood cell lysis buffer for 
three to five minutes to exclude red blood cells. The 
cells were then washed twice in DMEM medium. To 
determine the percentage of immune cells in the tumor, 
10,000 cells suspended in 100 μl PBS containing 10% 
fetal calf serum (FCS) were stained for 30 min at 4°C 
by using appropriate isotype controls and phycoerythrin-
conjugated anti-CD4, anti-F4/80, FITC-conjugated anti-Gr 
(BD Biosciences). After washing in PBS, the cells were 
analyzed on a FACSCalibur using CELLQUEST software 
(BD Biosciences).
Bacterial invasion and amplification assay 
in vitro
The day before infection, 1 × 106 B16F10 or 
RAW264.7 cells were seeded into 12-well plate with 
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500 µl appropriate cell culture medium. The cells were 
incubated at 37°C in 5% CO
2
. The cell culture medium 
was replaced with fresh medium one hour prior to 
infection. 1 × 107 CFU bacteria were added into each well. 
After infection, the plates were centrifuged at 250 g for 
5 minutes in order to bring cells and bacteria in contact 
and initiate infection. The plates were then incubated for 
one hour at 37°C in 5% CO
2
. Gentamicin (100 µg/ml) 
was added to the plates to kill extracellular bacteria one 
hour after infection. The gentamicin concentration was 
reduced to 10 µg/ml two hours later. At designated time 
points, cells were washed with PBS and lysed by 0.1% 
Triton X-100. Bacteria were released and plated onto LB 
agar plates by a serial dilution. CFUs on the plates were 
counted after overnight incubation at 37°C. 
Real-time quantitative PCR assay 
As mentioned above, tumor bearing mice were 
randomly divided into 5 groups, with each group 
containing 3 mice. Briefly, 1 × 105 S. enterica were 
intraperitoneally inoculated into the tumor-bearing mice. 
7 days post infection, the mice were sacrificed and total 
RNA was isolated from tumor tissues with TRIzol reagent 
(Invitrogen). cDNA was synthesized using ReverTra Ace® 
qPCR RT Kit (Toyobo). Real-time quantitative PCR was 
performed using AceQ qPCR SYBR Green Master Mix 
(Vazyme) to determine TNF-α and IL-1β expression. 
β-actin was used as a normalizing control.
Construction of complementing plasmids
The genes slyA, STM3120 and htrA were amplified 
for complementation using the primer sets as listed 
in Table 1. The resulting PCR products were purified 
using agarose gel electrophoresis and extracted from 
the gel using the gel extraction kit. The purified PCR 
products were inserted into pHQ003-F, a derivative of 
pET28a vector by ClonExpress II One Step Cloning 
Kit (Vazyme). The expression of the gene is controlled 
by a constitutive J23100 promoter and the FLAG tag is 
attached to the C terminus of complement protein. E.coli 
DH5α was transformed with the complement plasmid, and 
the positive clones were selected on LB plates containing 
Kanamycin. Plasmids bearing the correct insert were 
electroporated into the mutants, namely ∆slyA-pHQ(slyA), 
∆STM3120-pHQ(STM3120) and ∆htrA-pHQ(htrA), 
respectively. Plasmid-bearing mutants were selected on 
LB Kna plates. 
Western bolt analysis
∆slyA-pHQ(slyA), ∆STM3120-pHQ(STM3120) 
and ∆htrA-pHQ(htrA) were grown overnight in LB broth 
containing Kanamycin. Bacterial pellets were boiled in 
SDS loading buffer for 15 min. Blots were probed using 
monoclonal mouse antibody (F1804) against FLAG 
(Sigma).
Statistical analysis 
The results are presented as mean ± SEM 
using Graphpad software. Statistical significance for 
comparisons among two was analyzed using the student t 
test by SPSS. The level of significance was set at P < 0.05.
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